{"id":530681,"date":"2021-02-17T16:56:01","date_gmt":"2021-02-17T16:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=530681"},"modified":"2021-02-17T16:56:01","modified_gmt":"2021-02-17T16:56:01","slug":"hepatitis-d-virus-infection-competitive-assessment-report-2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatitis-d-virus-infection-competitive-assessment-report-2020-emerging-therapies-and-key-pharma-players-involved_530681.html","title":{"rendered":"Hepatitis D Virus Infection Competitive Assessment Report 2020: Emerging Therapies and Key Pharma Players involved"},"content":{"rendered":"
\"Hepatitis<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Hepatitis D Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market. A detailed picture of the Hepatitis D pipeline landscape is provided, which includes the disease overview and Hepatitis D treatment guidelines. <\/div>\n
DelveInsight launched a new report on Hepatitis D Virus Infection Pipeline Insights 2020<\/strong><\/a>.<\/div>\n
 <\/div>\n
Hepatitis D Pipeline Insight, 2020<\/strong><\/a> report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market. A detailed picture of the Hepatitis D pipeline landscape is provided, which includes the disease overview and Hepatitis D treatment guidelines. <\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
HDV is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as super-infection with HBV.<\/div>\n
 <\/div>\n
Request for a detailed sample copy of the report @https:\/\/www.delveinsight.com\/sample-request\/hepatitis-d-pipeline-insight<\/span><\/a><\/strong><\/div>\n
 <\/div>\n
 <\/div>\n
In the 7MM, the Total Diagnosed Prevalent cases of HDV were 204,976 cases in 2017. <\/strong><\/div>\n
 <\/div>\n
These cases are expected to grow with a significant CAGR in the study period 2017–2030.<\/div>\n
\n

Emerging Therapies:<\/strong><\/p>\n

1. Hepcludex\/Bulevirtide<\/p>\n

2. Lonafarnib<\/p>\n

3. JNJ-3989<\/p>\n

Key pharma players involved:<\/strong><\/p>\n

1. Hepcludex\/Bulevirtide<\/p>\n

2. Eiger Biopharmaceuticals<\/p>\n

3. Janssen Pharmaceuticals<\/p>\n

Click here and download free sample pages of the report.<\/strong><\/a><\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction<\/p>\n

2. Hepatitis D <\/p>\n

3. Hepatitis D Current Treatment Patterns<\/p>\n

4. Hepatitis D – DelveInsight’s Analytical Perspective<\/p>\n

5. Therapeutic Assessment<\/p>\n

6. Hepatitis D Late Stage Products (Phase-III)<\/p>\n

7. Hepatitis D Mid Stage Products (Phase-II)<\/p>\n

8. Early Stage Products (Phase-I)<\/p>\n

9. Pre-clinical Products and Discovery Stage Products<\/p>\n

10. Inactive Products<\/p>\n

11. Dormant Products<\/p>\n

12. Hepatitis D Discontinued Products<\/p>\n

13. Hepatitis D Product Profiles<\/p>\n

14. Hepatitis D Key Companies<\/p>\n

15. Hepatitis D Key Products<\/p>\n

16. Dormant and Discontinued Products<\/p>\n

17. Hepatitis D Unmet Needs<\/p>\n

18. Hepatitis D Future Perspectives<\/p>\n

19. Hepatitis D Analyst Review  <\/p>\n

20. Appendix<\/p>\n

21. Report Methodology<\/p>\n

Download our full report: https:\/\/www.delveinsight.com\/report-store\/hepatitis-d-pipeline-insight<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/span>
<\/span><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n<\/div>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP Hepatitis D Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market. A detailed picture of the Hepatitis D pipeline landscape is provided, which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-530681","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=530681"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530681\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=530681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=530681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=530681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}